Home › New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
 

Keywords :   


New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

2014-11-06 15:08:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to the time first

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Atlantic Tropical Weather Outlook
28.06Learning to listen to nursery pigs
28.06Incomes have risen 'at a crawl' says think tank
28.06Eastern North Pacific Tropical Weather Outlook
28.06Are rainy days ahead for cloud computing?
28.06Electric car battery charges in under five minutes in track test
28.06Debt relief orders can write off up to 50,000
27.06Strike could force Tata plant to shut next week
More »